TENX · Tenax Therapeutics, Inc.

Tenax Therapeutics strengthens its executive team with the appointment of Thomas R. Staab, II as permanent CFO, effective May 11, 2026, replacing interim CFO Thomas A. McGauley who will transition to consulting support. Staab's extensive experience as CFO at public healthcare firms like LENSAR (2020-2026), BioCryst (2011-2020), and Inspire (acquired by Merck) positions him to lead finance and accounting functions amid the company's Phase 3 development of levosimendan for PH-HFpEF. Compensation includes a competitive $428,000 base salary, 45% target bonus uncapped for outperformance, and significant inducement equity: 10,000 RSUs vesting rapidly (25% in 10 days) and 450,000 stock options vesting over four years. Severance terms provide 9 months of pay, pro-rated bonus, and COBRA for termination without Cause or for Good Reason, enhanced to 12 months post-Corporate Transaction. McGauley ensures continuity through the Q1 2026 10-Q filing. Awards approved under Nasdaq inducement rules without shareholder vote.